 Myron Levin
Concepts (797)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpes Zoster | 104 | 2023 | 336 | 19.330 |
Why?
| | Herpes Zoster Vaccine | 64 | 2023 | 159 | 17.880 |
Why?
| | Herpesvirus 3, Human | 85 | 2023 | 389 | 13.270 |
Why?
| | Antibodies, Viral | 64 | 2021 | 542 | 5.590 |
Why?
| | Chickenpox | 23 | 2023 | 100 | 5.450 |
Why?
| | Immunity, Cellular | 35 | 2023 | 270 | 5.010 |
Why?
| | Chickenpox Vaccine | 26 | 2023 | 69 | 4.180 |
Why?
| | Influenza Vaccines | 17 | 2023 | 500 | 3.120 |
Why?
| | Vaccines, Attenuated | 31 | 2023 | 114 | 2.870 |
Why?
| | HIV Infections | 37 | 2018 | 2459 | 2.840 |
Why?
| | Neuralgia, Postherpetic | 18 | 2019 | 45 | 2.750 |
Why?
| | Immunocompromised Host | 13 | 2019 | 200 | 2.690 |
Why?
| | Antiviral Agents | 27 | 2022 | 654 | 2.500 |
Why?
| | Adjuvants, Immunologic | 17 | 2023 | 207 | 2.430 |
Why?
| | Simplexvirus | 23 | 2016 | 86 | 2.160 |
Why?
| | Herpes Simplex | 17 | 2016 | 90 | 2.150 |
Why?
| | Vaccination | 33 | 2023 | 1222 | 2.140 |
Why?
| | Acyclovir | 26 | 2016 | 105 | 2.080 |
Why?
| | DNA, Viral | 24 | 2018 | 356 | 1.960 |
Why?
| | Papillomavirus Vaccines | 13 | 2018 | 221 | 1.860 |
Why?
| | Viral Envelope Proteins | 6 | 2021 | 80 | 1.680 |
Why?
| | Herpesvirus 1, Human | 10 | 2016 | 81 | 1.650 |
Why?
| | Pregnancy Complications, Infectious | 16 | 2020 | 296 | 1.650 |
Why?
| | T-Lymphocytes | 20 | 2019 | 1774 | 1.610 |
Why?
| | Aged | 91 | 2023 | 19657 | 1.580 |
Why?
| | Humans | 285 | 2023 | 118972 | 1.570 |
Why?
| | Aged, 80 and over | 47 | 2022 | 6561 | 1.550 |
Why?
| | Vaccines, Synthetic | 15 | 2023 | 128 | 1.510 |
Why?
| | Antiretroviral Therapy, Highly Active | 13 | 2017 | 260 | 1.490 |
Why?
| | Immunologic Memory | 12 | 2019 | 313 | 1.480 |
Why?
| | Influenza, Human | 12 | 2023 | 554 | 1.440 |
Why?
| | Immunization, Secondary | 13 | 2017 | 85 | 1.430 |
Why?
| | CD4-Positive T-Lymphocytes | 13 | 2023 | 984 | 1.410 |
Why?
| | Papillomavirus Infections | 9 | 2018 | 265 | 1.390 |
Why?
| | Middle Aged | 98 | 2022 | 27617 | 1.290 |
Why?
| | Female | 153 | 2022 | 61564 | 1.200 |
Why?
| | Double-Blind Method | 32 | 2022 | 1687 | 1.160 |
Why?
| | Male | 137 | 2022 | 57801 | 1.150 |
Why?
| | T-Lymphocyte Subsets | 6 | 2019 | 396 | 1.080 |
Why?
| | Vaccines, Inactivated | 9 | 2023 | 68 | 1.020 |
Why?
| | Chagas Disease | 5 | 2007 | 34 | 1.010 |
Why?
| | Viral Vaccines | 12 | 2014 | 90 | 1.010 |
Why?
| | Incidence | 22 | 2023 | 2424 | 1.000 |
Why?
| | Herpesvirus 2, Human | 6 | 2014 | 28 | 0.970 |
Why?
| | CD8-Positive T-Lymphocytes | 5 | 2018 | 702 | 0.960 |
Why?
| | Virus Latency | 4 | 2014 | 84 | 0.920 |
Why?
| | Interferon-gamma | 18 | 2022 | 736 | 0.920 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2019 | 61 | 0.920 |
Why?
| | Immune Sera | 4 | 2020 | 82 | 0.910 |
Why?
| | B-Lymphocytes | 9 | 2021 | 770 | 0.910 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2023 | 40 | 0.900 |
Why?
| | Injections, Intramuscular | 5 | 2022 | 116 | 0.880 |
Why?
| | Pneumococcal Vaccines | 3 | 2021 | 140 | 0.870 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 22 | 2021 | 827 | 0.870 |
Why?
| | Antibodies, Neutralizing | 12 | 2023 | 228 | 0.860 |
Why?
| | Respiratory Syncytial Virus Vaccines | 2 | 2019 | 24 | 0.840 |
Why?
| | Influenza A Virus, H1N1 Subtype | 6 | 2017 | 140 | 0.840 |
Why?
| | Age Factors | 17 | 2021 | 2995 | 0.830 |
Why?
| | Antibodies, Protozoan | 3 | 2007 | 28 | 0.830 |
Why?
| | Drug Resistance, Viral | 7 | 2009 | 98 | 0.830 |
Why?
| | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 6 | 2017 | 15 | 0.810 |
Why?
| | Rotavirus Infections | 3 | 2017 | 54 | 0.800 |
Why?
| | Down Syndrome | 2 | 2023 | 356 | 0.790 |
Why?
| | Vaccination Coverage | 2 | 2018 | 63 | 0.780 |
Why?
| | Influenza B virus | 6 | 2012 | 33 | 0.770 |
Why?
| | Anti-Retroviral Agents | 5 | 2018 | 208 | 0.760 |
Why?
| | Adult | 75 | 2023 | 31512 | 0.760 |
Why?
| | Infectious Disease Transmission, Vertical | 7 | 2020 | 156 | 0.730 |
Why?
| | Rotavirus Vaccines | 2 | 2017 | 48 | 0.720 |
Why?
| | Adenovirus Infections, Human | 4 | 2015 | 14 | 0.720 |
Why?
| | Receptors, Adrenergic, beta-1 | 3 | 2007 | 53 | 0.710 |
Why?
| | Clinical Trials as Topic | 15 | 2019 | 969 | 0.700 |
Why?
| | Th1 Cells | 3 | 2018 | 133 | 0.680 |
Why?
| | Insurance Claim Review | 1 | 2019 | 67 | 0.670 |
Why?
| | HIV | 4 | 2010 | 210 | 0.660 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 2015 | 113 | 0.660 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2017 | 39 | 0.660 |
Why?
| | Alphapapillomavirus | 4 | 2016 | 38 | 0.650 |
Why?
| | Cytomegalovirus Infections | 4 | 2015 | 187 | 0.640 |
Why?
| | Anti-HIV Agents | 6 | 2015 | 664 | 0.630 |
Why?
| | Dose-Response Relationship, Immunologic | 3 | 2016 | 82 | 0.620 |
Why?
| | Trypanosoma cruzi | 4 | 2007 | 23 | 0.620 |
Why?
| | Virus Shedding | 6 | 2017 | 41 | 0.620 |
Why?
| | Child | 57 | 2023 | 19129 | 0.610 |
Why?
| | Health Expenditures | 1 | 2019 | 174 | 0.600 |
Why?
| | Infant, Premature | 5 | 2020 | 480 | 0.600 |
Why?
| | CD4 Lymphocyte Count | 13 | 2017 | 267 | 0.600 |
Why?
| | Antibody Formation | 7 | 2023 | 276 | 0.590 |
Why?
| | Interleukin-2 | 7 | 2022 | 416 | 0.590 |
Why?
| | Cytosine | 3 | 2015 | 46 | 0.590 |
Why?
| | Herpesviridae Infections | 4 | 2015 | 142 | 0.580 |
Why?
| | Child, Preschool | 39 | 2020 | 9491 | 0.570 |
Why?
| | Pain | 6 | 2022 | 735 | 0.570 |
Why?
| | Antigens, Viral | 21 | 2017 | 181 | 0.560 |
Why?
| | Organophosphonates | 2 | 2015 | 94 | 0.560 |
Why?
| | Injections, Subcutaneous | 1 | 2016 | 138 | 0.550 |
Why?
| | Cytomegalovirus | 7 | 2006 | 144 | 0.550 |
Why?
| | Infant | 29 | 2020 | 8293 | 0.550 |
Why?
| | Immunoglobulin G | 9 | 2021 | 788 | 0.540 |
Why?
| | Adolescent | 51 | 2018 | 18480 | 0.540 |
Why?
| | Enzyme-Linked Immunospot Assay | 4 | 2018 | 33 | 0.530 |
Why?
| | Refrigeration | 2 | 2018 | 11 | 0.520 |
Why?
| | Follow-Up Studies | 21 | 2019 | 4596 | 0.520 |
Why?
| | Ribosomal Proteins | 2 | 2006 | 68 | 0.520 |
Why?
| | Uterine Cervical Neoplasms | 5 | 2016 | 216 | 0.520 |
Why?
| | Polyomavirus Infections | 1 | 2015 | 22 | 0.520 |
Why?
| | Health Care Costs | 1 | 2018 | 394 | 0.510 |
Why?
| | Immunity, Humoral | 3 | 2021 | 117 | 0.500 |
Why?
| | Skin Diseases | 1 | 2016 | 125 | 0.500 |
Why?
| | Oropharynx | 1 | 2014 | 41 | 0.500 |
Why?
| | Herpes Genitalis | 7 | 2014 | 16 | 0.490 |
Why?
| | Blood | 1 | 2014 | 100 | 0.490 |
Why?
| | Guanine | 13 | 2006 | 75 | 0.480 |
Why?
| | Viral Load | 11 | 2018 | 419 | 0.480 |
Why?
| | Polymerase Chain Reaction | 10 | 2019 | 1012 | 0.470 |
Why?
| | Immunogenicity, Vaccine | 4 | 2022 | 26 | 0.460 |
Why?
| | Vaccines | 3 | 2018 | 380 | 0.450 |
Why?
| | Immunization | 4 | 2014 | 412 | 0.450 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2016 | 359 | 0.450 |
Why?
| | Trigeminal Ganglion | 2 | 2003 | 22 | 0.450 |
Why?
| | Retrospective Studies | 16 | 2023 | 12978 | 0.450 |
Why?
| | Time Factors | 20 | 2021 | 6412 | 0.450 |
Why?
| | Herpes Labialis | 3 | 2013 | 8 | 0.450 |
Why?
| | Placebos | 8 | 2017 | 202 | 0.440 |
Why?
| | Aging | 10 | 2017 | 1670 | 0.440 |
Why?
| | United States | 17 | 2023 | 12555 | 0.430 |
Why?
| | Post-Exposure Prophylaxis | 2 | 2023 | 6 | 0.420 |
Why?
| | Sensory Receptor Cells | 1 | 2012 | 83 | 0.420 |
Why?
| | Communicable Diseases | 1 | 2014 | 132 | 0.420 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2021 | 1244 | 0.410 |
Why?
| | Quality of Life | 7 | 2021 | 2366 | 0.410 |
Why?
| | RNA, Viral | 20 | 2018 | 572 | 0.400 |
Why?
| | Pregnancy | 20 | 2020 | 5690 | 0.390 |
Why?
| | Infant, Newborn | 27 | 2020 | 5255 | 0.390 |
Why?
| | Databases, Factual | 4 | 2019 | 1231 | 0.380 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2012 | 185 | 0.380 |
Why?
| | Young Adult | 23 | 2017 | 10793 | 0.370 |
Why?
| | Human papillomavirus 18 | 5 | 2018 | 14 | 0.370 |
Why?
| | Human papillomavirus 16 | 5 | 2018 | 25 | 0.370 |
Why?
| | Glycoproteins | 2 | 2023 | 319 | 0.370 |
Why?
| | Poverty | 1 | 2013 | 444 | 0.350 |
Why?
| | Treatment Outcome | 19 | 2016 | 9342 | 0.350 |
Why?
| | Frail Elderly | 2 | 2020 | 107 | 0.340 |
Why?
| | Vaccines, Subunit | 5 | 2021 | 42 | 0.340 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 18 | 0.340 |
Why?
| | Activities of Daily Living | 3 | 2021 | 354 | 0.330 |
Why?
| | Varicella Zoster Virus Infection | 2 | 2018 | 21 | 0.320 |
Why?
| | Meningitis, Viral | 3 | 1997 | 22 | 0.310 |
Why?
| | Seasons | 3 | 2023 | 461 | 0.310 |
Why?
| | Meningitis | 1 | 2008 | 74 | 0.310 |
Why?
| | Hemagglutination Inhibition Tests | 7 | 2017 | 37 | 0.310 |
Why?
| | Research Design | 2 | 2013 | 969 | 0.300 |
Why?
| | Neurons | 6 | 2003 | 1345 | 0.300 |
Why?
| | Viremia | 5 | 2018 | 132 | 0.300 |
Why?
| | Cohort Studies | 11 | 2023 | 5116 | 0.300 |
Why?
| | Cytokines | 7 | 2018 | 1900 | 0.300 |
Why?
| | Animals | 31 | 2021 | 33381 | 0.290 |
Why?
| | Neoplasms | 3 | 2016 | 2179 | 0.290 |
Why?
| | Cells, Cultured | 19 | 2012 | 4077 | 0.290 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2017 | 99 | 0.280 |
Why?
| | Prospective Studies | 24 | 2019 | 6471 | 0.280 |
Why?
| | Immunocompetence | 4 | 2019 | 43 | 0.280 |
Why?
| | Protozoan Proteins | 1 | 2006 | 67 | 0.270 |
Why?
| | Risk Factors | 19 | 2019 | 9000 | 0.270 |
Why?
| | Virus Replication | 12 | 2018 | 405 | 0.270 |
Why?
| | Nucleic Acid Hybridization | 11 | 2006 | 193 | 0.270 |
Why?
| | Recurrence | 13 | 2019 | 975 | 0.260 |
Why?
| | Sleep Wake Disorders | 4 | 2013 | 241 | 0.260 |
Why?
| | Autoantibodies | 2 | 2007 | 1335 | 0.260 |
Why?
| | Viral Proteins | 5 | 2018 | 296 | 0.260 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2017 | 245 | 0.260 |
Why?
| | Depressive Disorder, Major | 4 | 2013 | 303 | 0.260 |
Why?
| | Cross Reactions | 6 | 2014 | 116 | 0.260 |
Why?
| | Severity of Illness Index | 14 | 2015 | 2674 | 0.260 |
Why?
| | Nucleosides | 1 | 2004 | 26 | 0.260 |
Why?
| | Cell Count | 2 | 2005 | 315 | 0.250 |
Why?
| | Influenza A virus | 5 | 2012 | 90 | 0.250 |
Why?
| | Vaccine Potency | 3 | 2019 | 6 | 0.250 |
Why?
| | Intestines | 2 | 2018 | 332 | 0.250 |
Why?
| | Interferons | 9 | 1982 | 151 | 0.250 |
Why?
| | Viral Plaque Assay | 7 | 2012 | 24 | 0.240 |
Why?
| | Herpesvirus 4, Human | 3 | 2014 | 126 | 0.240 |
Why?
| | Health Resources | 2 | 2019 | 132 | 0.240 |
Why?
| | Phosphoproteins | 1 | 2006 | 308 | 0.240 |
Why?
| | Nonlinear Dynamics | 1 | 2005 | 89 | 0.240 |
Why?
| | Monocytes | 7 | 2005 | 513 | 0.240 |
Why?
| | Neuralgia | 4 | 2010 | 120 | 0.240 |
Why?
| | Immunoassay | 2 | 2017 | 101 | 0.230 |
Why?
| | Genetic Variation | 1 | 2008 | 926 | 0.230 |
Why?
| | Antibody Affinity | 2 | 2021 | 55 | 0.230 |
Why?
| | Ganglia, Spinal | 2 | 1993 | 45 | 0.230 |
Why?
| | Developing Countries | 2 | 2016 | 255 | 0.230 |
Why?
| | Enterovirus Infections | 5 | 1995 | 164 | 0.220 |
Why?
| | Encephalitis | 2 | 1995 | 129 | 0.220 |
Why?
| | Cricetinae | 5 | 2007 | 262 | 0.220 |
Why?
| | Drug Combinations | 2 | 2022 | 291 | 0.220 |
Why?
| | CHO Cells | 3 | 2007 | 143 | 0.220 |
Why?
| | Pain Measurement | 8 | 2019 | 469 | 0.220 |
Why?
| | Lymphocyte Activation | 13 | 2015 | 1067 | 0.210 |
Why?
| | Papillomaviridae | 3 | 2011 | 101 | 0.210 |
Why?
| | Longitudinal Studies | 8 | 2018 | 2513 | 0.210 |
Why?
| | Virus Activation | 4 | 2010 | 80 | 0.210 |
Why?
| | Lymphocytosis | 1 | 2021 | 9 | 0.210 |
Why?
| | Fibroblasts | 10 | 2018 | 842 | 0.200 |
Why?
| | Fetal Diseases | 4 | 1991 | 148 | 0.200 |
Why?
| | Immunosenescence | 1 | 2021 | 4 | 0.200 |
Why?
| | Virology | 1 | 2001 | 20 | 0.200 |
Why?
| | Cell Separation | 1 | 2002 | 296 | 0.200 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 59 | 0.200 |
Why?
| | Case-Control Studies | 5 | 2018 | 3171 | 0.200 |
Why?
| | Herpes Simplex Virus Vaccines | 2 | 2012 | 3 | 0.200 |
Why?
| | Fluorescent Antibody Technique | 6 | 2016 | 410 | 0.190 |
Why?
| | HIV-1 | 5 | 2018 | 776 | 0.190 |
Why?
| | Hemophilia A | 2 | 1993 | 71 | 0.190 |
Why?
| | Immunoglobulin A | 3 | 2017 | 174 | 0.190 |
Why?
| | Antidepressive Agents | 2 | 2013 | 189 | 0.190 |
Why?
| | Health Services for the Aged | 1 | 2001 | 71 | 0.190 |
Why?
| | Enterovirus | 3 | 1995 | 72 | 0.190 |
Why?
| | Laboratories | 1 | 2001 | 97 | 0.180 |
Why?
| | Myocytes, Cardiac | 1 | 2004 | 472 | 0.180 |
Why?
| | Leukocytes, Mononuclear | 5 | 2010 | 509 | 0.180 |
Why?
| | Immunization, Passive | 4 | 1994 | 81 | 0.180 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1993 | 224 | 0.180 |
Why?
| | Immunoenzyme Techniques | 3 | 2006 | 195 | 0.180 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2022 | 233 | 0.180 |
Why?
| | Pneumococcal Infections | 2 | 2013 | 96 | 0.170 |
Why?
| | Immunization Schedule | 3 | 2016 | 188 | 0.170 |
Why?
| | Microbial Sensitivity Tests | 8 | 2005 | 302 | 0.170 |
Why?
| | Mice | 9 | 2021 | 15520 | 0.170 |
Why?
| | Cholera Toxin | 1 | 2018 | 28 | 0.170 |
Why?
| | Autophagosomes | 1 | 2018 | 21 | 0.170 |
Why?
| | Infant, Premature, Diseases | 3 | 1995 | 93 | 0.160 |
Why?
| | Lymphocytes | 8 | 1998 | 347 | 0.160 |
Why?
| | Liver Transplantation | 1 | 2006 | 847 | 0.160 |
Why?
| | Age Distribution | 3 | 2016 | 362 | 0.160 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2018 | 62 | 0.160 |
Why?
| | Sex Distribution | 3 | 2016 | 351 | 0.160 |
Why?
| | Immune Evasion | 1 | 2018 | 48 | 0.160 |
Why?
| | Viral Fusion Proteins | 1 | 2017 | 20 | 0.160 |
Why?
| | Drug Therapy, Combination | 4 | 2016 | 965 | 0.160 |
Why?
| | Depression | 3 | 2013 | 1132 | 0.160 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2017 | 57 | 0.160 |
Why?
| | Genes, Viral | 2 | 2006 | 93 | 0.160 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2017 | 47 | 0.160 |
Why?
| | Lysosomes | 1 | 2018 | 136 | 0.160 |
Why?
| | Regression Analysis | 2 | 2019 | 983 | 0.160 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2017 | 5 | 0.160 |
Why?
| | Disease Transmission, Infectious | 1 | 2018 | 56 | 0.150 |
Why?
| | Cost of Illness | 5 | 2014 | 258 | 0.150 |
Why?
| | Cryopreservation | 1 | 2018 | 99 | 0.150 |
Why?
| | Protein Subunits | 1 | 2018 | 211 | 0.150 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1474 | 0.150 |
Why?
| | Observational Studies as Topic | 1 | 2017 | 89 | 0.150 |
Why?
| | Cell Line | 14 | 2018 | 2707 | 0.150 |
Why?
| | Models, Biological | 1 | 2005 | 1715 | 0.150 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2017 | 69 | 0.150 |
Why?
| | Cost-Benefit Analysis | 3 | 2013 | 554 | 0.150 |
Why?
| | Infectious Mononucleosis | 2 | 1991 | 9 | 0.150 |
Why?
| | Receptors, Muscarinic | 1 | 1996 | 18 | 0.150 |
Why?
| | Recombinant Proteins | 2 | 2018 | 1308 | 0.150 |
Why?
| | Infusions, Intravenous | 2 | 2016 | 380 | 0.150 |
Why?
| | Africa | 1 | 2017 | 100 | 0.150 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 1996 | 44 | 0.150 |
Why?
| | Frailty | 1 | 2019 | 116 | 0.150 |
Why?
| | Antibodies, Bacterial | 3 | 2013 | 126 | 0.150 |
Why?
| | Hospitalization | 2 | 2023 | 1785 | 0.140 |
Why?
| | Foscarnet | 3 | 2003 | 19 | 0.140 |
Why?
| | Nelfinavir | 1 | 2016 | 8 | 0.140 |
Why?
| | Latex Fixation Tests | 1 | 1996 | 3 | 0.140 |
Why?
| | Comorbidity | 3 | 2019 | 1527 | 0.140 |
Why?
| | Erythema | 1 | 2016 | 24 | 0.140 |
Why?
| | Lopinavir | 1 | 2016 | 29 | 0.140 |
Why?
| | Atazanavir Sulfate | 1 | 2016 | 41 | 0.140 |
Why?
| | HIV Protease Inhibitors | 1 | 2016 | 64 | 0.140 |
Why?
| | Ribavirin | 2 | 1994 | 88 | 0.140 |
Why?
| | Simian virus 40 | 10 | 1977 | 21 | 0.130 |
Why?
| | Bone Marrow Transplantation | 3 | 1990 | 244 | 0.130 |
Why?
| | Peptide Fragments | 3 | 2007 | 702 | 0.130 |
Why?
| | Ritonavir | 1 | 2016 | 70 | 0.130 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2015 | 540 | 0.130 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2018 | 368 | 0.130 |
Why?
| | Dipeptides | 1 | 2015 | 51 | 0.130 |
Why?
| | Global Health | 1 | 2018 | 310 | 0.130 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1284 | 0.130 |
Why?
| | Host-Pathogen Interactions | 1 | 2018 | 300 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 197 | 0.130 |
Why?
| | Lymphocyte Subsets | 1 | 2015 | 76 | 0.130 |
Why?
| | Chronic Disease | 6 | 2019 | 1636 | 0.130 |
Why?
| | BK Virus | 1 | 2015 | 15 | 0.130 |
Why?
| | Guatemala | 1 | 2016 | 296 | 0.130 |
Why?
| | Brain Stem | 1 | 1995 | 104 | 0.130 |
Why?
| | Data Interpretation, Statistical | 3 | 2019 | 336 | 0.130 |
Why?
| | Reproducibility of Results | 5 | 2013 | 2874 | 0.130 |
Why?
| | Propylene Glycols | 1 | 2015 | 27 | 0.130 |
Why?
| | Survival Rate | 3 | 2016 | 1720 | 0.130 |
Why?
| | Medication Reconciliation | 1 | 2015 | 25 | 0.130 |
Why?
| | Sphingosine | 1 | 2015 | 35 | 0.130 |
Why?
| | Molecular Sequence Data | 5 | 2006 | 2871 | 0.130 |
Why?
| | Autophagy | 1 | 2018 | 315 | 0.130 |
Why?
| | Base Sequence | 8 | 2007 | 2159 | 0.120 |
Why?
| | Respiratory Syncytial Viruses | 4 | 1993 | 48 | 0.120 |
Why?
| | Infant, Newborn, Diseases | 1 | 2016 | 106 | 0.120 |
Why?
| | Chlamydia trachomatis | 2 | 1991 | 36 | 0.120 |
Why?
| | Histocompatibility Antigens Class I | 1 | 1996 | 177 | 0.120 |
Why?
| | Maus Elberfeld virus | 2 | 1991 | 5 | 0.120 |
Why?
| | Immunity, Mucosal | 2 | 2012 | 86 | 0.120 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2021 | 78 | 0.120 |
Why?
| | Maternal-Fetal Exchange | 3 | 1995 | 157 | 0.120 |
Why?
| | Laryngeal Diseases | 1 | 1994 | 21 | 0.120 |
Why?
| | Feces | 1 | 2017 | 396 | 0.120 |
Why?
| | Lymphoma | 1 | 2015 | 180 | 0.120 |
Why?
| | Hemagglutinins, Viral | 1 | 1994 | 6 | 0.120 |
Why?
| | Transfusion Reaction | 1 | 1995 | 79 | 0.120 |
Why?
| | Cross-Over Studies | 2 | 2013 | 456 | 0.120 |
Why?
| | Needs Assessment | 1 | 2016 | 327 | 0.120 |
Why?
| | DNA-Directed DNA Polymerase | 2 | 1992 | 45 | 0.120 |
Why?
| | Placenta | 2 | 1991 | 638 | 0.120 |
Why?
| | Analgesics | 3 | 2010 | 159 | 0.120 |
Why?
| | Autoantigens | 1 | 1996 | 397 | 0.120 |
Why?
| | Lamivudine | 2 | 2015 | 59 | 0.120 |
Why?
| | Zidovudine | 2 | 2015 | 77 | 0.120 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2013 | 26 | 0.120 |
Why?
| | Immunoglobulins, Intravenous | 5 | 1995 | 128 | 0.120 |
Why?
| | Ethics, Research | 1 | 2013 | 31 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 3 | 2013 | 465 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1440 | 0.110 |
Why?
| | Autoimmune Diseases | 1 | 1996 | 398 | 0.110 |
Why?
| | Health Status | 2 | 2010 | 726 | 0.110 |
Why?
| | Indoles | 1 | 2015 | 316 | 0.110 |
Why?
| | Research Subjects | 1 | 2013 | 40 | 0.110 |
Why?
| | Picornaviridae Infections | 2 | 1990 | 29 | 0.110 |
Why?
| | RNA Probes | 2 | 1991 | 14 | 0.110 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2014 | 170 | 0.110 |
Why?
| | Killer Cells, Natural | 1 | 1996 | 381 | 0.110 |
Why?
| | Chagas Cardiomyopathy | 2 | 2007 | 21 | 0.110 |
Why?
| | Risk Assessment | 4 | 2016 | 3057 | 0.110 |
Why?
| | Immunosuppressive Agents | 3 | 2015 | 681 | 0.110 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1996 | 267 | 0.110 |
Why?
| | Measles Vaccine | 1 | 2012 | 17 | 0.110 |
Why?
| | Colorado | 4 | 2018 | 4196 | 0.110 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2012 | 84 | 0.110 |
Why?
| | Flow Cytometry | 5 | 2017 | 1085 | 0.110 |
Why?
| | Human papillomavirus 31 | 1 | 2011 | 1 | 0.110 |
Why?
| | Drug Resistance, Microbial | 4 | 2001 | 67 | 0.110 |
Why?
| | Ureaplasma urealyticum | 1 | 1991 | 3 | 0.110 |
Why?
| | Cell Division | 4 | 2003 | 776 | 0.110 |
Why?
| | Meningitis, Aseptic | 1 | 1991 | 15 | 0.100 |
Why?
| | Macrophages | 3 | 2005 | 1324 | 0.100 |
Why?
| | Health Services Accessibility | 1 | 2018 | 781 | 0.100 |
Why?
| | T-Lymphocytes, Cytotoxic | 2 | 2011 | 158 | 0.100 |
Why?
| | Insurance, Health | 1 | 2014 | 244 | 0.100 |
Why?
| | Mutation | 5 | 2009 | 3457 | 0.100 |
Why?
| | Neurogenesis | 1 | 2012 | 105 | 0.100 |
Why?
| | Chorioamnionitis | 1 | 1991 | 37 | 0.100 |
Why?
| | Neural Stem Cells | 1 | 2012 | 120 | 0.100 |
Why?
| | Efficiency | 1 | 2012 | 89 | 0.100 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 1996 | 49 | 0.100 |
Why?
| | Myocardium | 1 | 1996 | 970 | 0.100 |
Why?
| | Linear Models | 2 | 2010 | 827 | 0.100 |
Why?
| | Gastroenteritis | 2 | 1989 | 64 | 0.100 |
Why?
| | Epidemiological Monitoring | 3 | 2018 | 49 | 0.100 |
Why?
| | Drug Design | 1 | 2012 | 160 | 0.100 |
Why?
| | Adjuvants, Pharmaceutic | 2 | 2022 | 11 | 0.100 |
Why?
| | Cervix Uteri | 1 | 2010 | 48 | 0.100 |
Why?
| | Sensitivity and Specificity | 3 | 2009 | 1795 | 0.100 |
Why?
| | Herpesviridae | 2 | 1981 | 20 | 0.090 |
Why?
| | Exanthema | 1 | 2011 | 77 | 0.090 |
Why?
| | Serum | 1 | 2010 | 63 | 0.090 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2010 | 29 | 0.090 |
Why?
| | Herpesvirus Vaccines | 1 | 2010 | 4 | 0.090 |
Why?
| | Pilot Projects | 1 | 2015 | 1419 | 0.090 |
Why?
| | Surveys and Questionnaires | 7 | 2021 | 4708 | 0.090 |
Why?
| | Genotype | 2 | 2008 | 1882 | 0.090 |
Why?
| | Respiratory Tract Infections | 1 | 1994 | 331 | 0.090 |
Why?
| | Rats | 3 | 2006 | 5392 | 0.090 |
Why?
| | Antigen-Presenting Cells | 5 | 2010 | 156 | 0.090 |
Why?
| | Immunoglobulin M | 1 | 1991 | 253 | 0.090 |
Why?
| | Enterovirus B, Human | 2 | 1988 | 24 | 0.090 |
Why?
| | Medicaid | 1 | 2014 | 411 | 0.090 |
Why?
| | Dermatomyositis | 1 | 1989 | 22 | 0.090 |
Why?
| | Receptors, Virus | 2 | 2006 | 78 | 0.090 |
Why?
| | Poliovirus | 2 | 2001 | 78 | 0.090 |
Why?
| | Epitopes | 3 | 2004 | 443 | 0.090 |
Why?
| | Hepatitis B Vaccines | 1 | 2009 | 46 | 0.090 |
Why?
| | Geriatrics | 1 | 2010 | 68 | 0.090 |
Why?
| | Placenta Diseases | 1 | 1989 | 14 | 0.090 |
Why?
| | Protozoan Infections | 1 | 1989 | 11 | 0.090 |
Why?
| | Drug Stability | 1 | 2009 | 153 | 0.090 |
Why?
| | Thymidine Kinase | 4 | 2001 | 14 | 0.090 |
Why?
| | Skin Diseases, Viral | 1 | 2008 | 5 | 0.090 |
Why?
| | Vagina | 1 | 2010 | 148 | 0.090 |
Why?
| | Oligonucleotide Probes | 1 | 1988 | 53 | 0.090 |
Why?
| | DNA Primers | 2 | 2009 | 533 | 0.080 |
Why?
| | Hydrocortisone | 1 | 2010 | 273 | 0.080 |
Why?
| | Geriatric Assessment | 1 | 2010 | 185 | 0.080 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 1986 | 75 | 0.080 |
Why?
| | Administration, Intranasal | 1 | 2008 | 79 | 0.080 |
Why?
| | Species Specificity | 2 | 2006 | 565 | 0.080 |
Why?
| | Interferon Type I | 1 | 1989 | 129 | 0.080 |
Why?
| | Anticonvulsants | 1 | 2010 | 184 | 0.080 |
Why?
| | Poisson Distribution | 2 | 2005 | 68 | 0.080 |
Why?
| | Muscles | 1 | 1989 | 333 | 0.080 |
Why?
| | Kinetics | 2 | 2010 | 1624 | 0.080 |
Why?
| | Evidence-Based Practice | 1 | 2010 | 193 | 0.080 |
Why?
| | Picornaviridae | 1 | 1988 | 18 | 0.080 |
Why?
| | Sequence Alignment | 1 | 2008 | 336 | 0.080 |
Why?
| | Amino Acid Sequence | 2 | 2006 | 2071 | 0.080 |
Why?
| | Lipid A | 2 | 2018 | 28 | 0.080 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 1988 | 24 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1996 | 1390 | 0.080 |
Why?
| | In Vitro Techniques | 6 | 2003 | 1094 | 0.080 |
Why?
| | Pertussis Vaccine | 1 | 2007 | 21 | 0.080 |
Why?
| | Veterans | 1 | 2018 | 1208 | 0.080 |
Why?
| | Prevalence | 4 | 2018 | 2326 | 0.080 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 709 | 0.080 |
Why?
| | Immunosorbent Techniques | 1 | 2007 | 18 | 0.080 |
Why?
| | Pregnancy Outcome | 1 | 2010 | 349 | 0.080 |
Why?
| | Quality-Adjusted Life Years | 1 | 2007 | 103 | 0.080 |
Why?
| | Spinal Cord | 2 | 2001 | 367 | 0.080 |
Why?
| | Cricetulus | 1 | 2007 | 98 | 0.070 |
Why?
| | Public Health | 1 | 2012 | 450 | 0.070 |
Why?
| | Receptor, IGF Type 2 | 1 | 2006 | 7 | 0.070 |
Why?
| | Data Collection | 1 | 2010 | 658 | 0.070 |
Why?
| | Vero Cells | 1 | 2006 | 69 | 0.070 |
Why?
| | Opportunistic Infections | 3 | 1993 | 42 | 0.070 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 81 | 0.070 |
Why?
| | Adenoviridae | 8 | 2005 | 191 | 0.070 |
Why?
| | COS Cells | 1 | 2007 | 184 | 0.070 |
Why?
| | Heparitin Sulfate | 1 | 2006 | 42 | 0.070 |
Why?
| | Neutralization Tests | 5 | 2012 | 66 | 0.070 |
Why?
| | Immunoglobulin Fragments | 1 | 2006 | 15 | 0.070 |
Why?
| | Research | 1 | 2010 | 411 | 0.070 |
Why?
| | NIH 3T3 Cells | 1 | 2006 | 139 | 0.070 |
Why?
| | Administration, Topical | 4 | 2013 | 141 | 0.070 |
Why?
| | Drug Administration Schedule | 2 | 2021 | 736 | 0.070 |
Why?
| | Random Allocation | 6 | 1992 | 344 | 0.070 |
Why?
| | Cyclic AMP | 1 | 2007 | 242 | 0.070 |
Why?
| | Immunoglobulin Variable Region | 1 | 2006 | 71 | 0.070 |
Why?
| | Meningococcal Vaccines | 1 | 2006 | 49 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 842 | 0.070 |
Why?
| | Nasopharyngeal Diseases | 1 | 1985 | 5 | 0.070 |
Why?
| | Logistic Models | 2 | 2010 | 1901 | 0.070 |
Why?
| | Endocytosis | 1 | 2006 | 156 | 0.070 |
Why?
| | Bone Marrow | 2 | 1984 | 255 | 0.070 |
Why?
| | Pneumonia, Viral | 2 | 1990 | 348 | 0.070 |
Why?
| | Flaviviridae Infections | 1 | 2005 | 1 | 0.070 |
Why?
| | GB virus C | 1 | 2005 | 1 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2009 | 1125 | 0.070 |
Why?
| | Motor Activity | 1 | 2010 | 660 | 0.070 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 1974 | 0.070 |
Why?
| | Organ Transplantation | 1 | 2008 | 165 | 0.070 |
Why?
| | Cell Differentiation | 1 | 2012 | 1753 | 0.070 |
Why?
| | Hepatitis, Viral, Human | 1 | 2005 | 26 | 0.070 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 536 | 0.070 |
Why?
| | HLA Antigens | 3 | 1987 | 230 | 0.070 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2016 | 38 | 0.060 |
Why?
| | Normal Distribution | 1 | 2005 | 24 | 0.060 |
Why?
| | Evaluation Studies as Topic | 3 | 1996 | 182 | 0.060 |
Why?
| | Disease Outbreaks | 1 | 1988 | 322 | 0.060 |
Why?
| | Mental Health | 1 | 2010 | 568 | 0.060 |
Why?
| | Autopsy | 2 | 2001 | 89 | 0.060 |
Why?
| | Neurons, Afferent | 1 | 2005 | 89 | 0.060 |
Why?
| | Transfection | 1 | 2007 | 888 | 0.060 |
Why?
| | Hybridization, Genetic | 8 | 1974 | 79 | 0.060 |
Why?
| | Receptors, Cholinergic | 1 | 2004 | 46 | 0.060 |
Why?
| | Macaca radiata | 2 | 2001 | 16 | 0.060 |
Why?
| | Epitope Mapping | 1 | 2004 | 49 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2006 | 356 | 0.060 |
Why?
| | Sex Factors | 2 | 2003 | 1781 | 0.060 |
Why?
| | Risk | 3 | 2016 | 853 | 0.060 |
Why?
| | Cell Adhesion Molecules | 1 | 2005 | 180 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2015 | 1945 | 0.060 |
Why?
| | Abdominal Neoplasms | 1 | 2003 | 28 | 0.060 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2003 | 64 | 0.060 |
Why?
| | Demography | 2 | 2018 | 274 | 0.060 |
Why?
| | RNA | 2 | 1988 | 833 | 0.060 |
Why?
| | Receptors, Cell Surface | 1 | 2005 | 367 | 0.060 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2004 | 144 | 0.060 |
Why?
| | Membrane Glycoproteins | 1 | 2005 | 446 | 0.060 |
Why?
| | 2-Aminopurine | 2 | 2007 | 10 | 0.060 |
Why?
| | Adaptive Immunity | 2 | 2017 | 161 | 0.050 |
Why?
| | Neuroblastoma | 1 | 2003 | 135 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2009 | 2062 | 0.050 |
Why?
| | Poliomyelitis | 2 | 2001 | 30 | 0.050 |
Why?
| | Heart Rate | 1 | 2006 | 729 | 0.050 |
Why?
| | Forecasting | 3 | 2010 | 353 | 0.050 |
Why?
| | Hepatitis C | 1 | 2004 | 217 | 0.050 |
Why?
| | Blotting, Western | 2 | 2015 | 1194 | 0.050 |
Why?
| | Cell Nucleus | 3 | 1991 | 580 | 0.050 |
Why?
| | Poliovirus Vaccine, Oral | 1 | 2001 | 22 | 0.050 |
Why?
| | Genome, Viral | 1 | 2002 | 124 | 0.050 |
Why?
| | Spondylarthropathies | 1 | 2021 | 6 | 0.050 |
Why?
| | Respirovirus Infections | 2 | 1991 | 21 | 0.050 |
Why?
| | Gene Expression | 1 | 2006 | 1489 | 0.050 |
Why?
| | Heart Transplantation | 1 | 2007 | 671 | 0.050 |
Why?
| | Sex Characteristics | 2 | 2017 | 671 | 0.050 |
Why?
| | Peripheral Nerves | 1 | 2001 | 65 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2001 | 287 | 0.050 |
Why?
| | Sleep | 1 | 2006 | 660 | 0.050 |
Why?
| | Secondary Prevention | 2 | 2013 | 227 | 0.050 |
Why?
| | Virion | 1 | 2001 | 78 | 0.050 |
Why?
| | Psoriasis | 1 | 2021 | 76 | 0.050 |
Why?
| | Canada | 2 | 2012 | 340 | 0.050 |
Why?
| | Amniotic Fluid | 3 | 1991 | 68 | 0.050 |
Why?
| | Enterotoxins | 2 | 1994 | 86 | 0.040 |
Why?
| | Saliva | 2 | 2010 | 188 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2478 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 1982 | 359 | 0.040 |
Why?
| | Saponins | 1 | 2018 | 7 | 0.040 |
Why?
| | Haptoglobins | 1 | 2018 | 49 | 0.040 |
Why?
| | Seroconversion | 1 | 2018 | 48 | 0.040 |
Why?
| | Encephalitis, Viral | 1 | 1998 | 44 | 0.040 |
Why?
| | Drug Compounding | 1 | 2018 | 90 | 0.040 |
Why?
| | Celiac Disease | 1 | 2021 | 267 | 0.040 |
Why?
| | Immunologic Techniques | 2 | 1994 | 40 | 0.040 |
Why?
| | Protein Precursors | 1 | 2018 | 126 | 0.040 |
Why?
| | Glucosides | 1 | 2017 | 39 | 0.040 |
Why?
| | Sterols | 1 | 2017 | 17 | 0.040 |
Why?
| | Inositol Phosphates | 1 | 2017 | 23 | 0.040 |
Why?
| | Health Surveys | 1 | 2019 | 454 | 0.040 |
Why?
| | Botswana | 1 | 2017 | 8 | 0.040 |
Why?
| | Zimbabwe | 1 | 2017 | 39 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 177 | 0.040 |
Why?
| | Antigens, Bacterial | 1 | 2017 | 116 | 0.040 |
Why?
| | Patient Safety | 1 | 2020 | 281 | 0.040 |
Why?
| | Tanzania | 1 | 2017 | 45 | 0.040 |
Why?
| | Biomarkers | 2 | 2018 | 3588 | 0.040 |
Why?
| | Internationality | 1 | 2018 | 152 | 0.040 |
Why?
| | Bisoprolol | 1 | 1996 | 5 | 0.040 |
Why?
| | Chemotaxis | 1 | 2017 | 137 | 0.040 |
Why?
| | Zambia | 1 | 2017 | 67 | 0.040 |
Why?
| | Recovery of Function | 1 | 2021 | 604 | 0.040 |
Why?
| | Plasma | 1 | 2018 | 224 | 0.040 |
Why?
| | Sinusitis | 1 | 1999 | 175 | 0.040 |
Why?
| | Immune Tolerance | 4 | 1998 | 334 | 0.040 |
Why?
| | Cerebrospinal Fluid | 2 | 1993 | 93 | 0.040 |
Why?
| | Acute Disease | 2 | 2011 | 940 | 0.040 |
Why?
| | Cross-Sectional Studies | 4 | 2011 | 4552 | 0.040 |
Why?
| | Leukemia, Lymphoid | 2 | 1986 | 27 | 0.040 |
Why?
| | Propanolamines | 1 | 1996 | 93 | 0.030 |
Why?
| | False Negative Reactions | 1 | 1996 | 57 | 0.030 |
Why?
| | Public Health Surveillance | 1 | 2016 | 58 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2010 | 1868 | 0.030 |
Why?
| | False Positive Reactions | 1 | 1996 | 115 | 0.030 |
Why?
| | Amniocentesis | 2 | 1991 | 24 | 0.030 |
Why?
| | Nevirapine | 1 | 2015 | 14 | 0.030 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2015 | 44 | 0.030 |
Why?
| | AIDS Dementia Complex | 1 | 2015 | 52 | 0.030 |
Why?
| | Depressive Disorder | 1 | 1998 | 333 | 0.030 |
Why?
| | Half-Life | 2 | 1992 | 147 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 239 | 0.030 |
Why?
| | Nausea | 1 | 2015 | 107 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1293 | 0.030 |
Why?
| | Breast Feeding | 1 | 2018 | 386 | 0.030 |
Why?
| | Chi-Square Distribution | 2 | 2013 | 525 | 0.030 |
Why?
| | Vomiting | 1 | 2015 | 123 | 0.030 |
Why?
| | Fingolimod Hydrochloride | 1 | 2015 | 32 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 296 | 0.030 |
Why?
| | Bromodeoxyuridine | 2 | 2007 | 76 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2015 | 64 | 0.030 |
Why?
| | Headache | 1 | 2015 | 128 | 0.030 |
Why?
| | Neutropenia | 1 | 2015 | 133 | 0.030 |
Why?
| | Belgium | 1 | 2014 | 9 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1996 | 301 | 0.030 |
Why?
| | Vaccines, Virus-Like Particle | 1 | 2014 | 3 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 1996 | 331 | 0.030 |
Why?
| | Culture Media | 2 | 1984 | 163 | 0.030 |
Why?
| | Metabolic Diseases | 1 | 2015 | 103 | 0.030 |
Why?
| | HLA-A2 Antigen | 1 | 2014 | 39 | 0.030 |
Why?
| | Rubella | 1 | 1974 | 22 | 0.030 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 1 | 1994 | 20 | 0.030 |
Why?
| | Tetanus Toxoid | 1 | 1994 | 37 | 0.030 |
Why?
| | Probability | 2 | 2005 | 305 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2014 | 31 | 0.030 |
Why?
| | Immunoblotting | 1 | 1994 | 307 | 0.030 |
Why?
| | Anemia | 1 | 2015 | 146 | 0.030 |
Why?
| | Seroepidemiologic Studies | 1 | 2014 | 146 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2004 | 403 | 0.030 |
Why?
| | Mortality | 1 | 2015 | 299 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2015 | 185 | 0.030 |
Why?
| | Developed Countries | 1 | 2013 | 32 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 989 | 0.030 |
Why?
| | Consensus | 1 | 2015 | 534 | 0.030 |
Why?
| | Drug Tolerance | 1 | 1992 | 78 | 0.030 |
Why?
| | Skin | 2 | 1989 | 657 | 0.030 |
Why?
| | Human papillomavirus 6 | 1 | 2011 | 3 | 0.030 |
Why?
| | Metabolomics | 1 | 2017 | 550 | 0.030 |
Why?
| | Ureaplasma Infections | 1 | 1991 | 3 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2016 | 360 | 0.030 |
Why?
| | Mycoplasma Infections | 1 | 1991 | 12 | 0.030 |
Why?
| | Safety | 1 | 1994 | 304 | 0.030 |
Why?
| | gamma-Globulins | 1 | 1991 | 19 | 0.030 |
Why?
| | Epstein-Barr Virus Nuclear Antigens | 1 | 1991 | 8 | 0.030 |
Why?
| | Absenteeism | 1 | 2012 | 38 | 0.030 |
Why?
| | Antibodies, Heterophile | 1 | 1991 | 13 | 0.030 |
Why?
| | Genitalia, Female | 1 | 2012 | 40 | 0.030 |
Why?
| | Inflammation | 2 | 2017 | 2566 | 0.030 |
Why?
| | Adenoviruses, Human | 1 | 1991 | 24 | 0.030 |
Why?
| | Hospitals, University | 1 | 1991 | 172 | 0.020 |
Why?
| | Matched-Pair Analysis | 1 | 2011 | 39 | 0.020 |
Why?
| | Bodily Secretions | 1 | 2010 | 2 | 0.020 |
Why?
| | North America | 1 | 2012 | 266 | 0.020 |
Why?
| | Paramyxoviridae Infections | 1 | 1990 | 10 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2015 | 521 | 0.020 |
Why?
| | Europe | 1 | 2012 | 356 | 0.020 |
Why?
| | Chlamydia Infections | 1 | 1991 | 65 | 0.020 |
Why?
| | Diagnosis, Differential | 3 | 2009 | 1384 | 0.020 |
Why?
| | Rhinovirus | 1 | 1990 | 40 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2015 | 671 | 0.020 |
Why?
| | Schwann Cells | 1 | 1990 | 27 | 0.020 |
Why?
| | Antigens | 2 | 1970 | 320 | 0.020 |
Why?
| | Bacterial Infections | 2 | 2001 | 227 | 0.020 |
Why?
| | Gestational Age | 2 | 1989 | 765 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2275 | 0.020 |
Why?
| | Serotyping | 2 | 1988 | 32 | 0.020 |
Why?
| | Antigens, Surface | 2 | 1987 | 156 | 0.020 |
Why?
| | DNA | 4 | 1988 | 1388 | 0.020 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 25 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1597 | 0.020 |
Why?
| | Self Administration | 1 | 2010 | 125 | 0.020 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2016 | 468 | 0.020 |
Why?
| | Hepatitis B Antibodies | 1 | 2009 | 10 | 0.020 |
Why?
| | Haplorhini | 7 | 1974 | 62 | 0.020 |
Why?
| | beta-Globins | 1 | 2009 | 16 | 0.020 |
Why?
| | Contraceptive Devices, Male | 1 | 1989 | 1 | 0.020 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 1989 | 6 | 0.020 |
Why?
| | Spermatocidal Agents | 1 | 1989 | 5 | 0.020 |
Why?
| | Ribonucleosides | 1 | 1989 | 6 | 0.020 |
Why?
| | In Situ Hybridization | 2 | 2001 | 311 | 0.020 |
Why?
| | Reference Values | 1 | 2011 | 774 | 0.020 |
Why?
| | Thymidine | 4 | 1980 | 62 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1993 | 1691 | 0.020 |
Why?
| | RNA, Antisense | 1 | 1988 | 19 | 0.020 |
Why?
| | Physical Examination | 1 | 2010 | 243 | 0.020 |
Why?
| | Astrocytes | 1 | 1990 | 177 | 0.020 |
Why?
| | Nasal Mucosa | 1 | 2009 | 97 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2490 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 176 | 0.020 |
Why?
| | Virus Cultivation | 4 | 1984 | 25 | 0.020 |
Why?
| | Measles | 1 | 1989 | 39 | 0.020 |
Why?
| | Mammalian orthoreovirus 3 | 1 | 1988 | 35 | 0.020 |
Why?
| | Reoviridae | 1 | 1988 | 38 | 0.020 |
Why?
| | Cancer Vaccines | 1 | 2009 | 139 | 0.020 |
Why?
| | Hepatitis | 1 | 1988 | 46 | 0.020 |
Why?
| | Fetus | 1 | 1992 | 690 | 0.020 |
Why?
| | DNA, Recombinant | 1 | 1988 | 42 | 0.020 |
Why?
| | Reoviridae Infections | 1 | 1988 | 55 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2010 | 254 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 1969 | 158 | 0.020 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1988 | 155 | 0.020 |
Why?
| | Telomere | 1 | 2010 | 204 | 0.020 |
Why?
| | Cytopathogenic Effect, Viral | 2 | 1982 | 18 | 0.020 |
Why?
| | Body Fluids | 1 | 1987 | 62 | 0.020 |
Why?
| | Australia | 1 | 2008 | 212 | 0.020 |
Why?
| | Cell Transformation, Neoplastic | 4 | 1977 | 317 | 0.020 |
Why?
| | Tritium | 6 | 1974 | 70 | 0.020 |
Why?
| | Noma | 1 | 1986 | 2 | 0.020 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 1988 | 109 | 0.020 |
Why?
| | Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2006 | 11 | 0.020 |
Why?
| | Anti-Bacterial Agents | 2 | 1999 | 1510 | 0.020 |
Why?
| | Mass Screening | 1 | 2014 | 1052 | 0.020 |
Why?
| | Valine | 1 | 2007 | 77 | 0.020 |
Why?
| | Open Reading Frames | 1 | 2007 | 121 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2008 | 299 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2007 | 276 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2484 | 0.020 |
Why?
| | Biliary Atresia | 1 | 1988 | 224 | 0.020 |
Why?
| | Ketones | 1 | 1986 | 45 | 0.020 |
Why?
| | Interleukin-4 | 2 | 1998 | 215 | 0.020 |
Why?
| | Reagent Kits, Diagnostic | 1 | 1985 | 42 | 0.020 |
Why?
| | Biopsy | 1 | 1989 | 1079 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2006 | 307 | 0.020 |
Why?
| | Intensive Care Units, Neonatal | 1 | 1988 | 178 | 0.020 |
Why?
| | Nectins | 1 | 2005 | 4 | 0.020 |
Why?
| | Lymphoproliferative Disorders | 1 | 1985 | 46 | 0.020 |
Why?
| | Streptococcus pneumoniae | 1 | 2006 | 141 | 0.020 |
Why?
| | Factor Analysis, Statistical | 1 | 2006 | 270 | 0.020 |
Why?
| | California | 1 | 2006 | 382 | 0.020 |
Why?
| | Toll-Like Receptor 2 | 1 | 2005 | 127 | 0.020 |
Why?
| | Toll-Like Receptors | 1 | 2005 | 167 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1985 | 204 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 1984 | 41 | 0.020 |
Why?
| | Hexuronic Acids | 1 | 1984 | 30 | 0.020 |
Why?
| | Glucuronic Acid | 1 | 1984 | 33 | 0.020 |
Why?
| | Alginates | 1 | 1984 | 51 | 0.020 |
Why?
| | Freezing | 1 | 1984 | 87 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 1989 | 578 | 0.020 |
Why?
| | Filtration | 1 | 1984 | 64 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 755 | 0.010 |
Why?
| | Culture Techniques | 4 | 1973 | 80 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 1984 | 273 | 0.010 |
Why?
| | Fetal Blood | 1 | 1985 | 272 | 0.010 |
Why?
| | RNA, Small Interfering | 1 | 2005 | 564 | 0.010 |
Why?
| | Transcription, Genetic | 4 | 1977 | 1323 | 0.010 |
Why?
| | Kidney | 8 | 1975 | 1353 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2007 | 1129 | 0.010 |
Why?
| | Stomatitis, Herpetic | 1 | 1982 | 5 | 0.010 |
Why?
| | Phosphonoacetic Acid | 1 | 1982 | 10 | 0.010 |
Why?
| | Prognosis | 1 | 2010 | 3443 | 0.010 |
Why?
| | Up-Regulation | 1 | 2005 | 872 | 0.010 |
Why?
| | Agammaglobulinemia | 1 | 1982 | 32 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2005 | 688 | 0.010 |
Why?
| | NF-kappa B | 1 | 2005 | 670 | 0.010 |
Why?
| | Brain | 1 | 1993 | 2490 | 0.010 |
Why?
| | Ulnar Nerve | 1 | 2001 | 17 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 1991 | 3730 | 0.010 |
Why?
| | Temperature | 1 | 1984 | 622 | 0.010 |
Why?
| | Administration, Oral | 2 | 1997 | 756 | 0.010 |
Why?
| | Cell Survival | 1 | 1984 | 1047 | 0.010 |
Why?
| | Embryo, Mammalian | 2 | 1973 | 220 | 0.010 |
Why?
| | Phytohemagglutinins | 1 | 1980 | 27 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2004 | 482 | 0.010 |
Why?
| | Serum Albumin | 1 | 2001 | 146 | 0.010 |
Why?
| | Neuroglia | 1 | 2001 | 157 | 0.010 |
Why?
| | Cell Communication | 1 | 1982 | 281 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2001 | 253 | 0.010 |
Why?
| | Phagocytosis | 1 | 1982 | 364 | 0.010 |
Why?
| | Leukocytes | 1 | 1981 | 290 | 0.010 |
Why?
| | Air Microbiology | 1 | 1980 | 41 | 0.010 |
Why?
| | Nasal Decongestants | 1 | 1999 | 9 | 0.010 |
Why?
| | Immunity, Maternally-Acquired | 1 | 1979 | 24 | 0.010 |
Why?
| | Carbon Isotopes | 4 | 1973 | 115 | 0.010 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 1999 | 39 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1979 | 154 | 0.010 |
Why?
| | Mitogens | 1 | 1978 | 57 | 0.010 |
Why?
| | Lectins | 1 | 1978 | 50 | 0.010 |
Why?
| | Steroids | 1 | 1999 | 153 | 0.010 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 1993 | 325 | 0.010 |
Why?
| | Rabbits | 1 | 1979 | 780 | 0.010 |
Why?
| | Cross Infection | 1 | 1980 | 205 | 0.010 |
Why?
| | Th2 Cells | 1 | 1998 | 164 | 0.010 |
Why?
| | Amanitins | 1 | 1977 | 4 | 0.010 |
Why?
| | Centrifugation, Density Gradient | 3 | 1971 | 41 | 0.010 |
Why?
| | Antigen-Antibody Complex | 1 | 1997 | 90 | 0.010 |
Why?
| | Interleukin-10 | 1 | 1998 | 306 | 0.010 |
Why?
| | Erythrocytes | 1 | 1982 | 641 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1999 | 1166 | 0.010 |
Why?
| | Adenoviridae Infections | 1 | 1975 | 14 | 0.010 |
Why?
| | Heart Defects, Congenital | 2 | 1993 | 703 | 0.010 |
Why?
| | Indicator Dilution Techniques | 1 | 1994 | 12 | 0.010 |
Why?
| | Patient Selection | 1 | 1999 | 676 | 0.010 |
Why?
| | Uridine | 2 | 1973 | 30 | 0.010 |
Why?
| | Centrifugation, Zonal | 2 | 1971 | 2 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 1999 | 693 | 0.010 |
Why?
| | Abortion, Therapeutic | 1 | 1974 | 5 | 0.010 |
Why?
| | Rubella virus | 1 | 1974 | 6 | 0.010 |
Why?
| | Cesium | 2 | 1971 | 17 | 0.010 |
Why?
| | Molecular Biology | 2 | 1971 | 58 | 0.010 |
Why?
| | Sucrose | 2 | 1971 | 104 | 0.010 |
Why?
| | Chlorides | 2 | 1971 | 137 | 0.010 |
Why?
| | Microscopy, Electron | 2 | 1990 | 413 | 0.010 |
Why?
| | Pulmonary Fibrosis | 1 | 1975 | 303 | 0.010 |
Why?
| | Complement Fixation Tests | 2 | 1984 | 5 | 0.010 |
Why?
| | Hemagglutination Tests | 1 | 1991 | 7 | 0.010 |
Why?
| | Genes | 1 | 1971 | 231 | 0.010 |
Why?
| | Stress, Psychological | 1 | 1998 | 972 | 0.010 |
Why?
| | Population Surveillance | 1 | 1993 | 413 | 0.010 |
Why?
| | Nonoxynol | 1 | 1989 | 5 | 0.010 |
Why?
| | Latex | 1 | 1989 | 12 | 0.010 |
Why?
| | Kidney Transplantation | 1 | 1975 | 585 | 0.010 |
Why?
| | Suspensions | 1 | 1987 | 30 | 0.000 |
Why?
| | Ribonucleases | 1 | 1987 | 53 | 0.000 |
Why?
| | Chloroquine | 1 | 1987 | 64 | 0.000 |
Why?
| | Deltaretrovirus | 1 | 1986 | 12 | 0.000 |
Why?
| | Binding, Competitive | 1 | 1985 | 205 | 0.000 |
Why?
| | Leukocyte Count | 1 | 1985 | 305 | 0.000 |
Why?
| | Mitosis | 1 | 1985 | 172 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1985 | 355 | 0.000 |
Why?
| | Serologic Tests | 1 | 1983 | 52 | 0.000 |
Why?
| | Histocompatibility Antigens | 2 | 1974 | 102 | 0.000 |
Why?
| | Infusions, Parenteral | 1 | 1982 | 37 | 0.000 |
Why?
| | Genetics, Microbial | 2 | 1971 | 9 | 0.000 |
Why?
| | Leukemia | 1 | 1983 | 208 | 0.000 |
Why?
| | Hospital Bed Capacity, 300 to 499 | 1 | 1980 | 5 | 0.000 |
Why?
| | Air Movements | 1 | 1980 | 11 | 0.000 |
Why?
| | Liver | 1 | 1988 | 1816 | 0.000 |
Why?
| | Hospital Units | 1 | 1980 | 24 | 0.000 |
Why?
| | Boston | 1 | 1980 | 76 | 0.000 |
Why?
| | Communicable Disease Control | 1 | 1980 | 72 | 0.000 |
Why?
| | Methods | 1 | 1978 | 67 | 0.000 |
Why?
| | p-Fluorophenylalanine | 1 | 1976 | 2 | 0.000 |
Why?
| | Cycloheximide | 1 | 1976 | 57 | 0.000 |
Why?
| | Hospitals, Pediatric | 1 | 1980 | 505 | 0.000 |
Why?
| | Inclusion Bodies, Viral | 1 | 1975 | 2 | 0.000 |
Why?
| | Cytoplasm | 1 | 1976 | 269 | 0.000 |
Why?
| | Cadaver | 1 | 1975 | 327 | 0.000 |
Why?
| | Transplantation, Homologous | 1 | 1975 | 415 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1983 | 2235 | 0.000 |
Why?
| | Genetic Code | 1 | 1971 | 20 | 0.000 |
Why?
| | Nucleic Acid Denaturation | 1 | 1971 | 30 | 0.000 |
Why?
| | Chymotrypsin | 1 | 1971 | 21 | 0.000 |
Why?
| | Platinum | 1 | 1971 | 38 | 0.000 |
Why?
| | Molecular Weight | 1 | 1971 | 343 | 0.000 |
Why?
| | DNA Replication | 1 | 1971 | 211 | 0.000 |
Why?
| | Carbon | 1 | 1971 | 170 | 0.000 |
Why?
| | Hot Temperature | 1 | 1971 | 334 | 0.000 |
Why?
| | Lung | 1 | 1975 | 3664 | 0.000 |
Why?
|
|
Levin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|